11β-甲基-19-去甲睾酮十二烷基碳酸酯

11β-甲基-19-去甲睾酮十二烷基碳酸酯[1](英語:11β-Methyl-19-nortestosterone 17β-dodecylcarbonate,藥物開發代碼:CDB-4754),簡稱11β-MNTDC 。是一種合成的口服蛋白同化甾類藥物,為19-去甲睾酮的衍生物。由美國國家兒童健康與人類發育研究所(NICHD)所開發,目前尚未上市的藥物[2][3][4][5]。其為雄激素酯衍生物,是11β-甲基-19-去甲睾酮英語11β-Methyl-19-nortestosterone(11β-MNT)與十二烷基碳酸形成的,同時也是11β-MNT的前體藥物[2][3][4][5]

11β-甲基-19-去甲睾酮十二烷基碳酸酯
臨床資料
其他名稱11β-MNTDC; CDB-4754
給藥途徑口服, 肌肉注射
藥物類別英語Drug class雄激素; 蛋白同化甾類; 雄激素酯; 孕激素
識別資訊
  • [(8R,9S,10R,11S,13S,14S,17S)-11,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] dodecyl carbonate
CAS號904901-01-5
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C32H52O4
摩爾質量500.76 g·mol−1
3D模型(JSmol英語JSmol
  • CCCCCCCCCCCCOC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](C)C[C@]12C
  • InChI=1S/C32H52O4/c1-4-5-6-7-8-9-10-11-12-13-20-35-31(34)36-29-19-18-28-27-16-14-24-21-25(33)15-17-26(24)30(27)23(2)22-32(28,29)3/h21,23,26-30H,4-20,22H2,1-3H3/t23-,26-,27-,28-,29-,30+,32-/m0/s1
  • Key:JVTCGMMASZPYDR-UIRZMXPTSA-N

11β-MNTDC與其姊妹藥物十一酸二甲雄酮英語Dimethandrolone undecanoate(DMAU)共同作為一種男性口服避孕藥被同期開發[6][7][8]

相比於睾酮,11β-MNTDC不會被5α還原酶代謝,所以雄激素性脫髮程度較低[9]

參考文獻

  1. ^ 两款男性口服避孕药已经通过了Ⅰ期临床试验. 上海醫藥. 2022, 43 (13): 58. 
  2. ^ 2.0 2.1 Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. Journal of Andrology. 2011, 32 (2): 183–192. PMID 20798389. doi:10.2164/jandrol.110.010371 . 
  3. ^ 3.0 3.1 Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, et al. The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects. The Journal of Steroid Biochemistry and Molecular Biology. October 2010, 122 (4): 212–218. PMC 2949447 . PMID 20599615. doi:10.1016/j.jsbmb.2010.06.009. 
  4. ^ 4.0 4.1 Hild SA, Attardi BJ, Koduri S, Till BA, Reel JR. Effects of synthetic androgens on liver function using the rabbit as a model. Journal of Andrology. 2010, 31 (5): 472–481. PMC 2943539 . PMID 20378929. doi:10.2164/jandrol.109.009365. 
  5. ^ 5.0 5.1 US 7820642,Blye RP, Kim HK,「Nandrolone 17β-carbonates」,發行於26 October 2010,指定於U.S. Department of Health and Human Services 
  6. ^ Thirumalai A, Page ST. Recent Developments in Male Contraception. Drugs. January 2019, 79 (1): 11–20. PMID 30588563. S2CID 56895132. doi:10.1007/s40265-018-1038-8. 
  7. ^ Second potential male birth control pill passes human safety tests. 
  8. ^ Yuen F, Thirumalai A, Pham C, Swerdloff RS, Anawalt BD, Liu PY, Amory JK, Bremner WJ, Dart C, Wu H, Hull L, Blithe DL, Long J, Wang C, Page ST. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. The Journal of Clinical Endocrinology and Metabolism. March 2020, 105 (3): e835–e847. PMC 7049261 . PMID 31976519. doi:10.1210/clinem/dgaa032. 
  9. ^ Shapiro LJ, Shapiro DB. Low Anabolic Profile in Assessing a Patient's Overall Hair Loss. 2018: 687–698. ISBN 978-4-431-56545-1. doi:10.1007/978-4-431-56547-5_72.